Northwest Biotherapeutics

NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead product, DCVax-L, is currently in a 312-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company’s second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a Phase I/II trial with DCVax for late stage ovarian cancer together with the University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.

Find a broker to begin trading NWBO now

Company Name Northwest Biotherapeutics
Market/Symbol NASDAQ: NWBO
Recent Price
Market Cap $92.32M
Avg. Daily Vol. (3m) 1,340,149
Price/Book N/A
Price/Cash Flow N/A
As of May. 25, 2018
*Source: QuoteMedia

Begin trading NWBO

 Find Broker



Northwest Biotherapeutics Latest News

May. 2, 2016 | 5:05 pm

Ask the CEO

Meet The Board of Directors

Peter Harper

Chariman & Board Member

Cary Sucoff

Board Member

Meet The Management Team

Linda F. Powers

Chief Executive Officer

Les Goldman

Senior Vice President, Business Development

Marnix L. Bosch

Chief Technical Officer

Alton L. Boynton

Chief Scientific Officer

Anthony Maida

Chief Operating Officer

Receive NWBO Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market